论文部分内容阅读
4月中旬,礼来制药董事长、总裁兼首席执行官李励达(John C.Lechleiter)博士当选为美国药品研究与制造商协会(PhRMA)主席。尽管李励达表示非常荣幸能在这样一个制药行业至关重要的历史时刻就任PhRMA的主席,但其实我们也看到了他面对的压力——2012年,很多药企将面临拳头产品专利过期、新品还未上市的挑战。尤其对以创新药为主要战略的药企来说更是考验。但李励达却非常有信心:“我们的目标十分清晰,必须要快速地把在研的产品推向市场。我们拥有礼来136年历史上最强
In mid-April, Dr. John C. Leechleiter, chairman and president and chief executive officer of Eli Lilly and Company, was elected as president of the Pharmaceutical Research and Manufacturers Association (PhRMA). Although Li Lida expressed his great pleasure in being chairman of PhRMA in such a crucial historical moment in the pharmaceutical industry, in fact we also saw the pressure he faced - in 2012, many pharmaceutical companies will face the expiration of their top-of-the-range product patents, Unlisted challenges. In particular, innovative drugs as the main strategy of the pharmaceutical companies is the test. However, Li Lida is very confident: ”Our goal is very clear, we must quickly research products in the market. We have Eli Lilly in the history of 136 the strongest